Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Dade Behring’s 8% January Stock Advance Builds On 129% Leap In 2003

This article was originally published in The Gray Sheet

Executive Summary

Dade Behring's focus on growing its clinical lab diagnostics business while reducing debt, combined with a rising profile on Wall Street and plans to enter the high-volume testing category, are buoying the firm's stock price

Related Content

Quidel, Digene Among Diagnostic Stocks To Rebound, Excel In 2003
Staar Warning Letter Presents Challenges For ICL Approval Timeline
Dade Behring goes public



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts